North America Leads in Alpha-1 Antitrypsin Deficiency Market Growth
The US AATD market is positioned for consistent growth, with a compound annual growth rate (CAGR) projected to exceed 6% between 2023 and 2030. This expansion is attributed to rising awareness, improved treatment modalities, and government initiatives supporting rare disease research. The global market for alpha-1 antitrypsin deficiency is forecast to expand at a CAGR of 12.8% and thereby increase from a value of US$3 Bn in 2024 to US$6.97 Bn by the end of 2031.